menu
    • menu

    Company profile for AbTis

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    AbTis is a biotechnology company transforming antibody conjugate therapies with its proprietary AbClick® platform. This innovative technology enables site-selective conjugation of therapeutic payloads without antibody modification, streamlining development and reducing costs. AbClick® allows precise control over half-life, drug-to-antibody ratio (DAR), and linker-payload stability, optimizing bioconjugate treatments such as ...
    AbTis is a biotechnology company transforming antibody conjugate therapies with its proprietary AbClick® platform. This innovative technology enables site-selective conjugation of therapeutic payloads without antibody modification, streamlining development and reducing costs. AbClick® allows precise control over half-life, drug-to-antibody ratio (DAR), and linker-payload stability, optimizing bioconjugate treatments such as ADCs, DACs, and AOCs. Acquired by Dong-A ST in 2023, AbTis partners with leading pharmaceutical companies to advance groundbreaking therapies for unmet medical needs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AbTiskorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    21, Geumhwa-ro 105beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.abtis.co.kr/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Shanghai Haoyuan Chemexpress Partners with AbTis for NextGene ADC
    Shanghai Haoyuan Chemexpress Partners with AbTis for NextGene ADC

    12 May 2025

    // PRESS RELEASE

    https://www.chemexpress.com/newVisotation/174

    PRESS RELEASE
    12 May 2025
    Share Share
    WuXi XDC & AbTis Partner to Advance Next-Gen ADCs
    WuXi XDC & AbTis Partner to Advance Next-Gen ADCs

    11 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/wuxi-xdc-and-abtis-announce-strategic-partnership-to-advance-next-generation-adcs-302398417.html

    PR NEWSWIRE
    11 Mar 2025
    Share Share
    Lonza, AbTis Partner to Extend Bioconjugation Capabilities
    Lonza, AbTis Partner to Extend Bioconjugation Capabilities

    29 Nov 2022

    // CONTRACTPHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2022-11-29/lonza-abtis-partner-to-extend-bioconjugation-capabilities/?widget=listSection

    CONTRACTPHARMA
    29 Nov 2022
    Share Share
    WuXi XDC & AbTis Sign MOU for Development and Manufacturing of ADC
    WuXi XDC & AbTis Sign MOU for Development and Manufacturing of ADC

    08 Jul 2022

    // PRESS RELEASE

    https://www.wuxibiologics.com/wuxi-xdc-and-abtis-sign-mou-for-development-and-manufacturing-of-antibody-drug-conjugates/

    PRESS RELEASE
    08 Jul 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search